Neoadjuvant Therapies for HER2+ Breast Cancer Clinical Trial
Neoadjuvant TCHP (Docetaxel/Carboplatin/Trastuzumab/Pertuzumab) Versus THP (Docetaxel/Trastuzumab/Pertuzumab) in Patients With Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (neoCARHP) : a Randomized, Open-label, Multicenter, Phase III Trial
The neoCARHP study was a randomized, open-label, multicenter, phase III, neoadjuvant trial. This study aimed to compare the efficacy and safety of docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) with docetaxel/trastuzumab/pertuzumab (THP) neoadjuvant setting for HER2-positive breast cancer. Patients will be randomized at a 1:1 ratio into TCHP or THP, respectively, and will be treated every 3 weeks before surgery.The primary endpoint was the percentage of pCR (ypT0/is, ypN0), which was defined as the absence of any residual invasive cancer in both the breast and axillary lymph nodes.
|Source||Guangdong Provincial People's Hospital|
|Status||Not yet recruiting|
|Start date||April 30, 2021|
|Completion date||April 30, 2025|